Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLU-IMMUNE trial of intratumoral influenza vaccine plus pembrolizumab in early pMMR colorectal cancer
2023-503228-17-00Phase 2Completed
- Sponsor
- Zealand University Hospital
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen and pembrolizumab in colorectal cancer (CRC), sponsored by Zealand University Hospital. Primary endpoint: Major pathological response rate. Started Apr 2023; status: completed.
02
Drugs
Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigenpembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-503228-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503228-17-00.